← brief for 2026-10-13 · Slowing decline

SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

This review combined results from many large drug trials. It found that SGLT2 inhibitors lower the risk of heart failure and kidney decline. These drugs also reduce the chance of dying from heart problems. This is strong evidence that these drugs protect the heart and kidneys.

Who did this work

Elbataa A · Mansour A · Elazab A · Alabed A · Masood RJ · Albogami AF · Alsalami JA · Hafeezallah AO · Alzahrani KM · Alotaibi KF · Hamza RAE · Akeil YM

Source

Paper · PubMed, the drug frontier · 2026 Oct 13
https://pubmed.ncbi.nlm.nih.gov/42865310/